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GlycosaminoglycansAbstract Background: Mucopolysaccharidoses (MPS) are autosomal recessive disorders charac-
terized by deﬁciency of lysosomal enzymes which break down the glycosaminoglycans (GAGs)
which results in widespread intra and extra-cellular accumulations of GAGs. Early initiation of
treatment, before the onset of irreversible tissue damage, clearly provides a favorable disease out-
come. Early detection might be afforded by analysis of amniotic ﬂuid.
Aim: To report our experience of prenatal diagnosis of MPS over 14-year period for cases
referred from medical centers throughout Egypt. Also to report the beneﬁt of prenatal genetic test-
ing in cases accompanied with genetic disorders.
Materials and methods: The present study included 33 pregnant women at risk of having a fetus
with MPS. Of these cases, 3 women had more than one pregnancy evaluated. All cases had a
detailed genetic ultrasound examination and a maternal serum alpha-fetoprotein (MSAFP) evalu-
ation during the second trimester of pregnancy. Thirty-eight amniocentesis procedures were per-
formed during the study for 2 dimensional electrophoresis (2-DEP) of GAGs.
Results: Positive consanguinity was present in near 70% (23/33) of the couples. Detailed genetic
ultrasound examination revealed a case with anencephaly and another one with a twin pregnancy.
160 K.R. Gaber et al.One case had a MSAFP of 3.6 multiple of the normal median (open neural tube defect). Another 2
cases had a risk of having Down syndrome. Results of the 2-DEP of GAGs in amniotic ﬂuid
revealed 36.8% (14/33) affected fetuses. During the ﬁnal counseling setting of the 14 cases with
abnormal results, 43% (6/14) elected to continue their pregnancy while 57% (8/14) elected termina-
tion.
Conclusion: Early prenatal screening and diagnosis, through a systematic multidisciplinary
approach, to all cases of mucopolysaccharidoses are recommended, to improve the quality of life
and to avoid the presence of other associated fetal developmental malformations.
 2015 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mucopolysaccharidoses (MPS) are autosomal recessive disor-
ders characterized by deﬁciency of lysosomal enzymes which
break down the glycosaminoglycans (GAGs). Their deﬁciency
results in widespread intra and extra-cellular accumulations of
GAGs [1]. They have been subdivided according to enzyme
defect and systemic manifestations [2].
Together with the lipidoses, MPS are the most common
lysosomal storage diseases. The overall incidence of each
group is in the region of 1:10.000 births [3].
Early initiation of treatment, before the onset of irreversible
tissue damage, clearly provides a favorable disease outcome.
However, early diagnosis is difﬁcult due to the rarity of these
disorders in combination with the wide variety of clinical
symptoms. Thus, much interest exists in prenatal detection
by amniocentesis. Early detection might be afforded by analy-
sis of amniotic ﬂuid because it contains fetal urine and cells
which commensurate with fetal age [4].
Prenatal genetic testing occurs in clinical settings, usually as
part of obstetric care. The prenatal screening is the ﬁrst step
toward prenatal diagnosis of congenital malformations [5].
Prenatal genetic testing has initiated a great debate about
reporting ﬁndings identiﬁed by a screening test to a population
booked for a speciﬁc diagnostic test [6]. However, the primary
purpose of prenatal testing is to gain information about the
health of a fetus that may be at increased risk for a chromo-
somal or other genetic condition [7]. This is in addition to
relieving parents’ anxiety over inheriting a genetic disease or
giving birth to a child with congenital abnormalities and this
is the major outcome [6,7].
The purpose of this study is to report our experience of pre-
natal diagnosis of mucopolysaccharidosis over 14-year period
(2000–2014) for cases referred from medical centers through-
out Egypt. Also we will emphasize on the importance and role
of prenatal genetic testing in all pregnancies, in screening for
accompanied genetic disorders, even in cases where prenatal
diagnosis is tailored to a speciﬁc disorder.
2. Patients and methods
2.1. Patients
This retrospective study was conducted at the Prenatal Diag-
nosis and Fetal Medicine Department and Biochemical Genet-
ics Department, National Research Centre, Egypt, over a
period of 14 years (2000–2014).The study included 36 pregnancies (14–22 weeks gestation)
in 33 families where a diagnosis with one of the MPS types has
been made in one or more of their previous children. The
exclusion criteria included previous cases with MPS IV.
The work was carried in accordance with the code of ethics
of the world association (declaration of Helsinki) for experi-
ments involving humans. A written informed consent was
obtained from all pregnant women included in this study after
full explanation of the study. The ethical approval was
obtained from the medical ethics committee at the National
Research Centre.
2.2. Methods
All cases in this study were subjected to:
n History taking, pedigree construction and clinical
examination.
n Two counseling settings: The ﬁrst entailed detailed explana-
tion of the condition to be studied and the investigations to
be carried. The second one included detailed explanation of
the results and options to be carried by the parents.
n Detailed genetic ultrasound examination at time of presen-
tation during the second trimester. This was done for detec-
tion of multiple pregnancies, placental location, fetal
growth, soft tissue markers and the presence of associated
fetal abnormalities.
n Measurement of maternal serum alpha-fetoprotein
(MSAFP): 5 cc venous blood was collected during the sec-
ond trimester of pregnancy (15 weeks+0–18 weeks+6). It
was measured in duplicate using commercially available
enzyme immunometric assay kit (EIA) Can Ag Diagnostics,
Sweden. The values were transformed to multiple of the
normal median (MoM) after adjusting the gestational age.
A MSAFP above 2.5 MoM (cutoff limit) was considered
elevated and carries a high risk for open neural tube defects,
and the case was offered a second detailed ultrasound
examination, if not detected before. MSAFP MoM was
evaluated according to gestational age and older maternal
age at the expected time of delivery for risk of Down syn-
drome. A risk of 1:270 or more was considered elevated,
and the case was offered the opportunity for amniotic ﬂuid
study for fetal chromosomes.
n Extraction of GAGs from cell-free amniotic ﬂuid: The
amniotic ﬂuid samples were centrifuged and the superna-
tants were taken and used for the extraction of GAGs by
formation of complexes with alcian blue 8GX. In this pro-
cedure 3 ml of centrifuged amniotic ﬂuid was mixed with
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plex was formed and after centrifugation it was separated
and precipitated. The complex was dissociated by shaking
with 4 mol/l NaCl and methanol. Free alcian blue was pre-
cipitated by the addition of 0.1 mol/l Na2CO3 and water.
GAGs were precipitated from clear supernatant by the
addition of ethanol and the precipitate after centrifugation
was taken up in 20 ll water [8,9].
n Two-dimensional electrophoresis: After extraction of
GAGs from the amniotic ﬂuid, 2-DEP was carried out on
cellulose acetate sheets. Two microliters of GAGs were
applied and the separation proceeded for 1 h as ﬁrst run
(pyridine:glacial acetic acid:water; 10:1:89 v/v) and then
for 3 h as second run (0.1 M barium acetate buffer). The
GAGs were separated into discrete spots and were easily
located after staining for 1 h with 0.05% alcian blue solu-
tion containing 50 mmol/l MgCl2 in 50 mmol/l sodium ace-
tate buffer (pH 5.8) and washing with 5% acetic acid
solution. Two spots should be present in any 2-DEP of
amniotic ﬂuid before further interpretation. The ﬁrst is
the hyaluronic acid spot verifying its amniotic ﬂuid nature
and the second is the small chondroitin spot to verify the
presence of fetal urine indicating functioning fetal kidneys
[9,10].
3. Results
The studied cases were referred from all over Egypt for prena-
tal diagnosis of MPS. Positive consanguinity was present in
near 70% (23/33) of the couples. The maternal age at time
of delivery ranged between 22 and 38 years. The gestational
age at time of the procedures ranged between 15+0 and
19+0 weeks.
Of these cases, 3 women had more than one pregnancy eval-
uated during the course of the study, making them 37 pregnan-
cies evaluated and counseled. All cases had a detailed genetic
ultrasound examination which revealed a case with anenceph-
aly and another one with a twin pregnancy (Dichorionic–
Diamniotic). All cases had a MSAFP evaluation during the
second trimester of pregnancy. Of these cases, one case had
a MSAFP of 3.6 MoM and conﬁrmed by ultrasound to have
an open neural tube defect (anencephaly). Another 2 cases
had a risk of having Down syndrome of more than 1:270 based
on MSAFP measurement and the maternal age at the expected
time of delivery.
Thirty-eight amniocentesis procedures were performed dur-
ing the study (2 separate samples in the twin pregnancy). For
the 38 amniotic ﬂuid samples, analysis was performed in all
of them for the type of MPS at risk. And, in the 2 samplesTable 1 Results of amniotic ﬂuid biochemical studies in pregnancie
MPS among the 14 affected pregnancies.
Pregnancies at risk of having diﬀerent types of MPS Number of aﬀec
13 pregnancies at risk of having MPS I fetus 5 fetuses with M
7 pregnancies at risk of having MPS II fetus 4 fetuses with M
9 pregnancies at risk of having MPS VI fetus 4 fetuses with M
7 pregnancies at risk of having MPS III fetus 1 fetus with MP
CS = chondroitin sulfate; HS = heparan sulfate; DS = dermatan sulfateat additional risk for Down syndrome, amniotic ﬂuid study
revealed normal karyotypes. During the ﬁnal counseling set-
tings of the 14 cases with abnormal results, 43% (6/14) elected
to continue their pregnancy and 57% (8/14) elected
termination.
Results of 2-DEP of GAGs in amniotic ﬂuid revealed
36.8% (14/38) affected fetuses with MPS and the distribution
of the types among them is shown in Table 1. Examples of
the abnormal electrophoresis patterns for MPS VI compared
with the normal pattern are illustrated in Fig. 1.
4. Discussion
Consanguineous marriages are frequent among Egyptians and
lead to high incidence of recessive genetic disorders. In the
present study, positive consanguinity was detected in 70%
(23/33) of the couples. The study performed by Temtamy
et al. in 2010 stated that the rate of consanguineous marriages
in Egypt may reach up to 40% [11]. The high rate of consan-
guinity in our study agrees with the rate reported (87.5%)
among the pregnancies subjected to prenatal diagnosis of lipi-
dosis in the same community [12].
MPS can be diagnosed prenatally by measuring the enzyme
activity in culture for amniocytes or in chorionic villi and also
in leukocytes and plasma of fetal blood obtained by cordocen-
tesis. It can also be achieved by the analysis of pertinent
metabolites in amniotic ﬂuid through 2-DEP of GAGs [13].
Analysis of cell-free amniotic ﬂuid offers the advantage of
being a rapid and reliable method, and eliminating the require-
ment for culture for amniocytes. There is a general agreement
that fetal urine is a major contributor to the formation of
amniotic ﬂuid from mid-pregnancy [14].
In this study we did not include any case for prenatal diag-
nosis of MPS IV, as we will get a normal electrophoretic pat-
tern with spots of chondroitin sulfate and hyaluronic acid and
not a spot of keratan sulfate which is the diagnostic marker for
MPS IV in electrophoresis. Burlingame et al. in 1981 stated
that keratan sulfate is probably bound to or associated with
a certain amount of chondroitin sulfate as judged by its elec-
trophoretic mobility before and after the use of enzymatic
digestion by chondroitinase ABC [15,16].
MPS I (Hurler syndrome) results from deﬁciency of the
enzyme alpha-L-iduronidase (IDUA). The 2-DEP of GAGs
in the amniotic ﬂuid of an affected fetus with MPS I shows
excretion of dermatan sulfate and heparan sulfate, in addition
to excretion of chondroitin sulfate and hyaluronic acid which
are normally present in the amniotic ﬂuid. In our study 13
pregnancies were scheduled for prenatal diagnosis of MPS I.
One of the women had a previous history of affected twins
and then she was tested in two successive pregnancies whichs at risk of having MPS fetuses and the distribution of types of
ted pregnancies with each type of MPS Results of amniocentesis
PS I (35.7%) DS, HS, CS, HA
PS II (28.6%) DS, HS, CS, HA
PS VI (28.6%) DS, CS, HA
S III (7.1%) Hep, HS, CS, HA
; Hep = heparin; HA= hyaluronic acid.
Figure 1 Example of abnormal pattern of electrophoretic separation of GAGs in amniotic ﬂuid in MPS VI fetus (A) compared with a
normal pattern (B): CS = chondroitin sulfate, DS = dermatan sulfate, HA= hyaluronic acid.
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of 2 affected children (one of them died) and then she was
tested in three successive pregnancies. The fetus tested in
2009 was normal, while the other 2 pregnancies were in 2012
and 2013 and resulted in 2 affected fetuses. This highlights
the importance of 2-DEP of amniotic ﬂuid as a rapid, sensitive
and reliable method for the diagnosis of MPS. Another
woman had a history of previously affected children and
scheduled for prenatal diagnosis and the result was a normal
fetus. One of the women had an affected child and was tested
in 2 successive pregnancies, the result was one normal fetus
and one affected. In the other 4 females (each of them had a
previously affected child) the electrophoretic patterns were
normal in 3 of them while one fetus was affected.
MPS II (Hunter) is an X-linked disorder caused by deﬁ-
ciency of iduronate-2-sulfatase (IDS) enzyme. In this study 7
pregnancies were tested for prenatal diagnosis of MPS II and
3 fetuses were proved to be affected. In one of the 3 affected
pregnancies the woman had previously 3 affected boys and
in the culture of Egypt, to have a normal boy is a strong
motive to be pregnant several times. In the other 2 affected
pregnancies, each one had only one affected child. For the
other 4 normal fetuses, the women had a history of a previ-
ously affected child. One of the 4 cases with MPS II had anen-
cephaly with elevated levels of MSAFP.
MPS type III (Sanﬁlippo) results from deﬁciency in 4 differ-
ent enzymes of heparan metabolism giving subtypes A, B, C
and D which are similar phenotypically and they have also
similar electrophoretic pattern of GAGs separation [17]. Elec-
trophoresis can discriminate between broad classes of MPS but
cannot distinguish subgroups. Seven pregnant females were
scheduled for prenatal diagnosis of MPS III. One of them
had abnormal pattern with increased excretion of heparan sul-
fate and had a history of a previously affected child while the
other 6 had normal patterns. Four out of the 6 normal preg-
nancies had a history of one affected child. In the other 2 nor-
mal fetuses, one had a history of previously affected twins and
the other one had one normal and two affected children.In MPS VI (Maroteaux–Lamy Syndrome), the deﬁciency is
in arylsulfatase B enzyme (N-acetylgalactosamine-4-sulfatase)
which leads to accumulation of dermatan sulfate in different
tissues [18]. Nine cases in the present study were scheduled
for prenatal diagnosis of MPS VI and 2-DEP of GAGS
revealed 4 affected fetuses. All of the 9 cases had a history of
a previously affected child with MPS VI. Fig. 1 shows the elec-
trophoretic pattern of one of the 4 MPS VI fetuses included in
this study with dermatan sulfate spot in addition to chondroi-
tin sulfate and hyaluronic acid spots which are normally
excreted in the amniotic ﬂuid.
Prenatal diagnostic techniques have rendered decision mak-
ing about reproduction more complicated for the obstetrician
than any preceding era. Prenatal genetic testing, including both
screening and diagnostic procedures, has a clear effect on the
experience of pregnancy for many women. All pregnancies
included in the study had screening tests although the main
indication for referral, to the Prenatal Diagnosis Clinics–
NRC, was a history of a previously affected child with MPS
in the family. This included a detailed genetic ultrasound
examination and MSAFP measurement during the second tri-
mester. All cases at risk elected to perform diagnostic tests, in
order to obtain indicative results concerning their fetuses.
Pregnancies at risk for Down syndrome suspected by bio-
chemical screening (MSAFP) and older maternal age had
amniotic ﬂuid analysis for MPS I and MPS VI in addition to
chromosomal study. All results were normal and the cases con-
tinued their pregnancies with normal outcome. In these men-
tioned cases, the primary purpose of testing was to relieve
anxiety of parents over inheriting a genetic disease and to
avoid the birth of a baby with an unexpected congenital abnor-
mality other than that indicated for referral.
In one of the cases presenting with history of MPS II, the
MSAFP showed increased level (3.6 MoM), and ultrasound
examination revealed an open neural tube defect (anencephalic
fetus). The case requested to perform amniocentesis to conﬁrm
the cause of referral. The 2-DEP of amniotic ﬂuid revealed an
affected fetus with MPS II. Closed cephalocele is a new,
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patients affected by Hunter syndrome. Manara et al. in 2011
reported that nearly 1 out of 4 Hunter patients presents with
a meningeal or brain parenchymal herniation at the level of
the anterior or middle cranial fossa [19].
Counseling before and after prenatal genetic testing is cru-
cial. In an ideal counseling, the patient should be told that
there is no ‘‘right’’ decision to be made, and that they are sup-
ported in whatever decision they make [20]. In this study, the
type of the test offered either screening or diagnostic, was
clearly explained. In addition, the degree of accuracy of the
test in their particular situation was clearly stated. Following
delivery of the results, 57% (8/14) of the couples with affected
cases elected termination of pregnancy, while the remaining
chose continuation. For all couples who elected to continue
their pregnancies, with an abnormal result, there was false reli-
gious and social pressure about termination. This, in addition
to the feeling of guilt experienced by many couples for termi-
nation of pregnancy.
In conclusion, mucopolysaccharidoses which are multisys-
tem disorders, present with a constellation of clinical ﬁndings.
Early prenatal screening and diagnosis to all cases are recom-
mended through a systematic multidisciplinary approach. This
is to improve the quality of life and to avoid the presence of
other associated fetal developmental malformations. Qualita-
tive determination of glycosaminoglycans in amniotic ﬂuid
using the 2-DEF is proved to be a rapid, sensitive and accurate
method, but requires care in application and experience in
interpretation. It helps couples to have a normal infant and
prevent having another affected child.
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